Organon deal to strengthen Sun Pharma’s innovative portfolio, says Kirti Ganorkar

Sun Pharma’s proposed $11.75 billion acquisition of Organon could reshape its global growth strategy by strengthening its presence in women’s health, biosimilars and key international markets. The deal is expected to expand Sun Pharma’s innovative medicines portfolio and significantly deepen its reach across China, Europe and Latin America.